Scarica l'app Stockscreener
86.08
0.17%
-0.465
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$86.55
Aprire:
$87.275
Volume 24 ore:
1.08M
Relative Volume:
0.54
Capitalizzazione di mercato:
$12.13B
Reddito:
$622.01M
Utile/perdita netta:
$-271.86M
Rapporto P/E:
-40.07
EPS:
-2.1484
Flusso di cassa netto:
$-45.87M
1 W Prestazione:
+6.00%
1M Prestazione:
+18.21%
6M Prestazione:
+31.53%
1 anno Prestazione:
+413.06%
Intervallo 1D:
$83.79
$87.57
Intervallo di 1 settimana:
$78.81
$87.83
Portata 52W:
$14.30
$87.83
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
86.08 | 12.19B | 622.01M | -271.86M | -45.87M | -2.1484 |
VRTX
Vertex Pharmaceuticals Inc
|
522.41 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.94 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.98 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.29 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.97 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Neutral |
| 2023-12-04 | Iniziato | BofA Securities | Buy |
| 2023-09-19 | Iniziato | Citigroup | Neutral |
| 2023-07-21 | Iniziato | TD Cowen | Outperform |
| 2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Ripresa | Goldman | Buy |
| 2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-19 | Iniziato | Citigroup | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Iniziato | Goldman | Neutral |
| 2020-01-21 | Iniziato | SVB Leerink | Underperform |
| 2019-12-13 | Iniziato | Oppenheimer | Perform |
| 2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-27 | Reiterato | B. Riley FBR | Buy |
| 2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
| 2019-10-03 | Iniziato | Robert W. Baird | Outperform |
| 2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Arrowhead Pharmaceuticals stock hits 52-week high at 84.65 USD - Investing.com
Price to book forward of Arrowhead Pharmaceuticals, Inc. – NASDAQ:ARWR - TradingView
Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh - TradingView
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100 - Moomoo
H.C. Wainwright reiterates Arrowhead Pharma stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Arrowhead Pharma stock rating at buy - Investing.com
ARWR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $110 - Moomoo
ARWR Maintained by Chardan Capital -- Price Target Steady at $90 - GuruFocus
Arrowhead Pharmaceuticals Price Target Maintained With a $90.00/Share by Chardan Capital - Moomoo
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development ProgramsSlideshow (NASDAQ:ARWR) 2026-06-30 - Seeking Alpha
Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $90 - Moomoo
Arrowhead Pharmaceuticals eyes Q3 SHASTA data as REDEMPLO approvals build momentum - MSN
Arrowhead Pharmaceuticals, Inc.(NasdaqGS: ARWR) dropped from Russell 2000 Index - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell Midcap Value Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell Midcap Growth Benchmark - marketscreener.com
Arrowhead Pharmaceuticals Inc R&D Webinar (Virtual) Transcript - GuruFocus
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell 1000 Value Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell 1000 Growth Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from Russell 2000 Dynamic Index - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell 3000E Value Benchmark - marketscreener.com
Is Arrowhead Pharmaceuticals on the Cusp of a Major Breakout - Kavout | AI
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ARWR) - TradingView
Arrowhead Pharmaceuticals, Inc. Actuals & Estimates (SWB:HDP1) - TradingView
HDP1 Forecast — Price Target — Prediction for 2027 - TradingView
A2AGYB Forecast — Price Target — Prediction for 2027 - TradingView
ARWR Forecast — Price Target — Prediction for 2027 - TradingView
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree - AOL.com
Liquidity Mapping Around (ARWR) Price Events - Stock Traders Daily
Arrowhead Pharmaceuticals (ARWR) Leads Healthcare Stocks with St - GuruFocus
Arrowhead Pharmaceuticals gets EC approval for REDEMPLO in FCS - grafa.com
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals (ARWR) Receives EU Approval for REDEMP - GuruFocus
EU approves Arrowhead's REDEMPLO for rare fat disorder FCS - Stock Titan
The Insider Report: Stocks Celebrate Peace and a New Fed Chapter - Benzinga
Are Arrowhead Pharmaceuticals’ (ARWR) Board Moves and RNAi Webinars Quietly Reframing Its Risk Narrative? - Sahm
ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It? - Stocktwits
Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update - Sahm
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars - Business Wire
Arrowhead Pharmaceuticals stock hits 52-week high at $82.30 By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals Inc (ARWR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arrowhead Pharmaceuticals Inc (ARWR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arrowhead Pharmaceuticals Inc - TradingKey
Director Matthew Cohen granted 11,882 RSUs at Arrowhead Pharmaceuticals (ARWR) - Stock Titan
Arrowhead Pharmaceuticals Rises as Recent Clinical Updates and EU Catalyst Keep Focus on Plozasiran - Quiver Quantitative
Arrowhead Pharmaceuticals stock hits 52-week high at $82.30 - Investing.com
ARWR Maintained by Leerink Partners -- Price Target Raised to $7 - GuruFocus
Arrowhead Pharmaceuticals (ARWR) director files Form 3 showing zero share ownership - Stock Titan
Veteran healthcare investor Matt Cohen joins Arrowhead (ARWR) board with $887K RSU grant - Stock Titan
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
3.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):